title: ONO-6818 Cortech/Ono.
abstract: ONO-6818 (CP-955) is the lead compound in a series of orally bioavailable neutrophil elastase inhibitors licensed from Cortech and under investigation by Ono for the potential treatment of inflammatory conditions, such as rheumatoid arthritis, inflammatory bowel disease and chronic obstructive pulmonary disease (COPD) [174095]. ONO-6818 was in phase I studies for COPD in Japan as of December 1999 [366431]. Phase I trials for this indication in Japan and the US were ongoing in September 2001 [368565], [422782], [446138]. As of June 2002, however, a number of unconfirmed reports stated that the compound had moved into phase II trials in Japan and was in preparation for phase II trials in the US [456596], [456597].
authors.affiliation: Novartis Respiratory Research Centre, Horsham, West Sussex, UK. alexandre.trifilieff@pharma.novartis.com
authors.forename: Alexandre
authors.initials: A
authors.lastname: Trifilieff
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D019272:Leukocyte Elastase / Q000037:antagonists & inhibitors; D010069:Oxadiazoles / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D004791:Enzyme Inhibitors; C419152:ONO 6818; D010069:Oxadiazoles; D011744:Pyrimidinones; D019272:Leukocyte Elastase